FDA Advisory Committee recommends MS drug

An advisory committee of the US Food and Drug Administration has recommended that the multiple sclerosis drug, fingolimod, be approved, according to Novartis, the drug’s manufacturer. The drug is an oral therapy that has a novel mode of action.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland